Back to top
more

Acadia Healthcare (ACHC)

(Delayed Data from NSDQ)

$42.08 USD

42.08
1,159,269

-0.41 (-0.96%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $42.06 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (55 out of 251)

Industry: Medical - Hospital

Zacks News

Cardinal Health (CAH) Buys Specialty Networks to Boost Workflow

Cardinal Health (CAH) acquires Specialty Network to technologically strengthen its specialty therapeutic areas. The acquisition also supports the company's ongoing Navista Network.

Cardinal Health (CAH) Beats on Q2 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) second-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Thermo Fisher (TMO) Q4 Earnings Top Estimates, Gross Margin Down

Strength in PPI business contributed to Thermo Fisher's (TMO) fourth-quarter revenue growth.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Cencora (COR) Beats on Q1 Earnings & Revenues, Ups 2024 Outlook

Cencora's (COR) first-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Here's Why You Should Retain Neogen (NEOG) Stock for Now

Investors are optimistic about Neogen (NEOG) on strong growth in Animal and Food Safety businesses.

Charles River (CRL) Launches Animal-Free Endotoxin Test

Charles River's (CRL) latest launch expands on Charles River's existing Trillium rCR vial product.

ClearPoint's (CLPT) Neuro Systems to Boost Neurosurgeries

ClearPoint (CLPT) is likely to provide effective neurosurgical operations with the installation of the ClearPoint Prism Neuro Laser Therapy System and the Neuro Navigation System.

Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment

Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.

Bruker (BRKR) to Advance in Lab Automation With New Buyout

This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."

AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

AngioDymics' (ANGO) new FDA-approved Auryon XL Catheter is likely to boost PAD treatment by eliminating access site complications in Atherectomy procedures.

BD (BDX) Collaborates With Hamilton to Benefit Researchers

Becton, Dickinson and Company (BDX) partners with Hamilton to boost its portfolio of single-cell multiomics solutions, enabling researchers to perform more confident experiments.

Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?

Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Universal Health (UHS) Up 5.3% in 6 Months: More Room to Run?

Universal Health's (UHS) rising patient volumes and better pricing position the company well for growth.

Surmodics' (SRDX) New Device to Boost Its Thrombectomy Platform

Surmodics (SRDX) new addition to its Pounce Thrombectomy Platform is recommended for use in vessels with a diameter between 2 mm and 4 mm for clot removal.

Dexcom (DXCM) Set to Solidify Its Business Throughout EMEA

Dexcom (DXCM), opening a new manufacturing facility in the West of Ireland, is expected to boost production of rtCGM sensors and create employment.

McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group

McKesson (MCK) is seeking buyers for the Canadian Rexall Pharmacy Group. The business is currently amid its second round of offers, with no set deadline for submissions.

Stryker's (SYK) Gamma4 Expansion Set to Boost Fracture Healing

With the expansion of Gamma4, Stryker (SYK) is looking forward to strengthening its nailing system and solidifying its position as a leading choice in Orthopedic procedures.

PacBio's (PACB) New PanDNA Kit Ready to Boost DNA Extraction

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

Stryker's (SYK) New Tech Aims to Improve Surgeon's Efficiency

Stryker's (SYK) Blueprint Mixed Reality Guidance system aims to benefit shoulder arthroplasty surgeons by improving efficiency and minimizing errors.

GE Healthcare (GEHC) Buys MIM Software to Boost Imaging Tools

GE Healthcare (GEHC) is likely to enhance medical imaging capabilities and boost powerful AI solutions with the acquisition of MIM Software. Financial details are kept under cover.

Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents

Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.

Why Acadia (ACHC) is a Smart Addition to Your Portfolio Now

Acadia Healthcare's (ACHC) top line is poised to gain from rising admissions and patient days.

Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?

Here is how Acadia Healthcare (ACHC) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.